Zobrazeno 1 - 10 of 965 pro vyhledávání: '"Adam JM"'
1
Akademický článek
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
Autor: Grether U; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Foxton RH; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Gruener S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Korn C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Kimbara A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Osterwald A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Zirwes E; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Uhles S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Thoele J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Colé N; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Rogers-Evans M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Röver S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Nettekoven M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Martin RE; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Adam JM; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fingerle J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bissantz C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Guba W; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Alker A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Szczesniak AM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Porter RF; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Toguri TJ; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Revelant F; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Poirier A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Perret C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Winther L; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Caruso A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fezza F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy., Maccarrone M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; European Center for Brain Research (CERC), Santa Lucia Foundation IRCCS, Rome, Italy., Kelly MEM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Fauser S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ullmer C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 12; Vol. 15, pp. 1426446. Date of Electronic Publication: 2024 Jul 12 (Print Publication: 2024).
Zobrazit plný text záznamu
2
Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter.
Autor: Zampaloni C; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Mattei P; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Bleicher K; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; SixPeaks Bio, Basel, Switzerland., Winther L; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Thäte C; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; Preclinical Sciences and Translational Safety, Janssen Pharmaceutica, Beerse, Belgium., Bucher C; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Adam JM; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; AutoChem R&D, Mettler-Toledo International, Greifensee, Switzerland., Alanine A; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; Independent consultant, Cambridge, Great Britain., Amrein KE; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Baidin V; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA., Bieniossek C; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Bissantz C; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Boess F; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Cantrill C; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Clairfeuille T; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Dey F; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Di Giorgio P; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., du Castel P; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Dylus D; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Dzygiel P; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Felici A; Discovery Microbiology, Aptuit (Verona) Srl, an Evotec Company, Verona, Italy., García-Alcalde F; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Haldimann A; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Leipner M; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Leyn S; Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Louvel S; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Misson P; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Osterman A; Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA., Pahil K; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA., Rigo S; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Schäublin A; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; SixPeaks Bio, Basel, Switzerland., Scharf S; Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Schmitz P; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Stoll T; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Trauner A; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Zoffmann S; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.; Therapeutics Discovery, Janssen Pharmaceutica, Beerse, Belgium., Kahne D; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA., Young JAT; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland., Lobritz MA; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. michael.lobritz@roche.com., Bradley KA; Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. kenneth.bradley@roche.com.
Publikováno v: Nature [Nature] 2024 Jul; Vol. 631 (8022), pp. E17.
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Kniha
132.3. F. 9 Nov. '59. ⟨? Sir George Hay.⟩ Adam.—JM ii. 439.
Autor: Johnson, Samuel
Publikováno v: The Letters of Samuel Johnson, with Mrs. Thrale's genuine letters to him, Vol. 1: 1719-1774; Letters 1-369: 132.3. F. 9 Nov. '59. ⟨? Sir George Hay.⟩ Adam.—JM ii. 439., 1784.
Externí odkaz: http://dx.doi.org/10.1093/oseo/instance.00046641
Zobrazit plný text záznamu
7
Periodical
Risks of bridge collapses are real and set to rise - here's why.
Autor: Adam JM, Makoond N, Riveiro B, Buitrago M
Publikováno v: Nature [Nature] 2024 May; Vol. 629 (8014), pp. 1001-1003.
Zobrazit plný text záznamu
8
Akademický článek
Arresting failure propagation in buildings through collapse isolation.
Autor: Makoond N; ICITECH, Universitat Politècnica de València, Valencia, Spain., Setiawan A; ICITECH, Universitat Politècnica de València, Valencia, Spain., Buitrago M; ICITECH, Universitat Politècnica de València, Valencia, Spain., Adam JM; ICITECH, Universitat Politècnica de València, Valencia, Spain. joadmar@upv.es.
Publikováno v: Nature [Nature] 2024 May; Vol. 629 (8012), pp. 592-596. Date of Electronic Publication: 2024 May 15.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje